Prenatal exposure to modafinil alters locomotor behaviour and leucocyte phagocytosis in mice
Jazyk angličtina Země Chorvatsko Médium print
Typ dokumentu časopisecké články
PubMed
30267529
DOI
10.24869/psyd.2018.356
Knihovny.cz E-zdroje
- MeSH
- fagocytóza účinky léků MeSH
- gestační stáří MeSH
- leukocyty účinky léků MeSH
- lokomoce účinky léků MeSH
- luminiscenční měření MeSH
- luminol MeSH
- modafinil škodlivé účinky MeSH
- modely nemocí na zvířatech * MeSH
- myši inbrední ICR MeSH
- myši MeSH
- těhotenství MeSH
- věkové faktory MeSH
- zpožděný efekt prenatální expozice * MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- luminol MeSH
- modafinil MeSH
BACKGROUND: Modafinil is a psychostimulant drug prescribed mainly for treatment of narcolepsy but is used as a "smart drug" by wide populations to increase wakefulness, concentration and overall mental performance. The aim of this study was to assess potential developmental toxicity of modafinil. MATERIALS AND METHODS: Pregnant female mice were given either saline or modafinil (50 mg/kg orally) from gestational day (GD) 3 to GD 10 and then a challenge dose on the GD 17. The male offspring were treated analogously at the age of 10 weeks. Changes in the spontaneous locomotor/exploratory behaviour and anxiogenic profile in the open-field test were assessed in naive animals, after an acute and 8th modafinil dose and the challenge dose following a 7-day wash-out period. One month after completion of the behavioural study, the leukocyte phagocytosis was examined by zymosan induced and luminol-aided chemiluminiscence assay in vitro. RESULTS: The most important finding of this study was the immunosuppressing effect on leukocyte activity, hypolocomotion and increased behavioural response to modafinil-induced psychostimulation caused by prenatal exposure to the same drug. We did not detect significantly altered anxiety-related behaviour in any group disregarding the pre- and postnatal treatments. CONCLUSION: This is the first evidence of developmental toxicity of modafinil which needs to be taken into account as a potential risk factor when modafinil is administered to women who may become or are pregnant.
Citace poskytuje Crossref.org